In an effort to give timely notice to the pharmacy community concerning important pharmacy topics, the Department of Health and Mental Hygiene’s (DHMH) Maryland Medicaid Pharmacy Program (MMPP) has developed the Maryland Medicaid Pharmacy Program Advisory. To expedite information timely to the pharmacy and prescriber communities, an email network has been established which incorporates the email lists of the Maryland Pharmacists Association, EPIC, CARE, Long Term Care Consultants, headquarters of all chain drugstores and prescriber associations and organizations. It is our hope that the information is disseminated to all interested parties. If you have not received this email through any of the previously noted parties or via DHMH, please contact the MMPP representative at 410-767-1455.

Invega® (Brand) tablets on DAW 6 Program

In some instances the multisource brand name drug is required over its generic equivalents, because the branded drug is less costly than its generic counterpart. This happens most often in cases of newly released generics. When manufacturer rebates are taken into consideration, the brand name drug has a lower net cost to the State. Effective Wednesday, November 25, 2015, MMPP will cover brand Invega® tablets over its generic counterpart (paliperidone extended release tablets). Claims for Invega® tablets must be submitted with DAW 6 and will be priced appropriately. Claims for Invega® tablets with any other DAW code will reject. A DHMH Medwatch form will not be required.

- Invega® is still a non-preferred drug and will require a prior authorization by the prescriber.
- If any problems are encountered during the on-line claim adjudication, contact Xerox 24-hour Help Desk at 800-932-3918 for additional system overrides related to the use of the correct DAW code (for example, if there is other primary insurance).
- All Advisories are available online on DHMH’s web link at:
  http://mmcp.dhmh.maryland.gov/pap/SitePages/Provider%20Advisories.aspx